ENTITY

Fujian Haixi Pharmaceuticals (2637 HK)

8
Analysis
Health Care • China
Fujian Haixi Pharmaceuticals is a commercial-stage innovative pharmaceutical company that researches, develops, produces, and sells both generic and innovative drugs. Its product portfolio includes generic drugs for various therapeutic areas and innovative drug candidates for retinal diseases and oncology. The company was founded in 2012 and is headquartered in Fuzhou, Fujian Province, China.
more
Exchange Announcement • 24 Sep 2026 17:58

Interim Report 2026

Exchange Announcement • 16 Sep 2026 20:20

Voluntary Announcement - Hx9428 Latest Data From Phase I And Phase Ii Clinical Studies For The Treatment Of Neovascular Age-Related Macular Degeneration (Namd)

Exchange Announcement • 02 Sep 2026 19:16

Voluntary Announcement - Hx9428 Successfully Completes Phase I Clinical Study In Neovascular Age-Related Macular Degeneration And Submits Phase Iia Ind Application For New Indication Of Diabetic Macular Edema

Exchange Announcement • 28 Aug 2026 20:43

Announcement Of Interim Results For The Six Months Ended 30 June 2026

Exchange Announcement • 17 Aug 2026 19:45

Voluntary Announcement - Hx9428 For The Treatment Of Neovascular Age-Related Macular Degeneration Granted Fast Track Designation (Ftd) By The U.S. Fda

x